Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07339059 · ClinicalTrials.gov registry record · Phase 2
SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer
A Phase 2 study of Small Cell Lung Cancer (SCLC) and Extensive Stage Small Cell Lung Cancer (ES-SCLC), sponsored by Bindu R Potugari.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT07339059: Recruiting Phase 2 study of Small Cell Lung Cancer (SCLC) and Extensive Stage Small Cell Lung Cancer (ES-SCLC), sponsored by Bindu R Potugari.
NCT07339059 is a Phase 2 study of Small Cell Lung Cancer (SCLC) and Extensive Stage Small Cell Lung Cancer (ES-SCLC) that is actively recruiting participants, run by Bindu R Potugari. The registered enrollment target is 35 participants, below the 291-participant average among 12 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07339059, a Phase 2 study of Small Cell Lung Cancer (SCLC) and Extensive Stage Small Cell Lung Cancer (ES-SCLC), is actively recruiting participants, sponsored by Bindu R Potugari.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if the combination of sacituzumab govetican (SG) and atezolizumab/durvalumab is effective in controlling cancer tumor growth in adults with extensive stage small cell lung cancer. These drugs are FDA approved individually in different cancers. This combination is evaluated in breast cancer and showed promising combination. The effectiveness of this treatment combination will be measured by changes in tumor size and appearance of new tumors. Participants in the trial will: * receive treatment SG and immunotherapy every 21 days for up to 2 years or until it is no longer works for the patient. * CT scans at 6weeks for first 6 cycles and then every 9-12 weeks and MRI brain every 12 weeks. * provide tissue (optional) and blood for additional testing (learn about the cancer).
Primary Outcome
To evaluate the rate of disease control at 12 weeks for patients with extensive stage small cell lung cancer treated with Sacituzumab govitecan (SG) plus atezolizumab or durvalumab as maintenance therapy after induction treatment with chemotherapy and immunotherapy. Disease Control at 12 weeks is defined as a best response by RECIST 1.1 of CR, PR, non-CR, non-PR, or stable disease assessed by RECIST 1.1 and reported within 12 weeks (+/- 2 weeks) from the initiation of study therapy. Participant
Conditions Studied
Interventions
- DRUG Sacituzumab govitecan
- DRUG Atezolizumab
- DRUG Durvalumab
Study Locations (1)
Michigan
- Henry Ford Cancer- Detroit - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2029-12-01 |
| Phase | Phase 2 |
What NCT07339059 shows while recruiting
NCT07339059 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 291-participant average among 12 other Small Cell Lung Cancer (SCLC) trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Small Cell Lung Cancer (SCLC) appearing as the primary indexed condition, and to 3 interventions - of which Sacituzumab govitecan is the first listed.
NCT07339059 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT07339059 about?
NCT07339059 is a clinical study titled "SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer". The goal of this clinical trial is to learn if the combination of sacituzumab govetican (SG) and atezolizumab/durvalumab is effective in controlling cancer tumor growth in adults with extensive stage small cell lung cancer. These drugs are FDA approved individually in different cancers. This combina...
What is the current status of trial NCT07339059?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2026-02-01. Estimated completion is 2029-12-01.
What conditions does trial NCT07339059 study?
This clinical trial studies the following conditions: Small Cell Lung Cancer (SCLC), Extensive Stage Small Cell Lung Cancer (ES-SCLC).
What interventions are being tested in trial NCT07339059?
The interventions under investigation include: Sacituzumab govitecan (DRUG), Atezolizumab (DRUG), Durvalumab (DRUG).
Who is sponsoring clinical trial NCT07339059?
This trial is sponsored by Bindu R Potugari, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07339059 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Cell Lung Cancer (SCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07339059's enrollment target sits among peer trials
35 13th of 12 the lowest of 12 other Small Cell Lung Cancer (SCLC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small Cell Lung Cancer (SCLC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
RECRUITING · Phase 2
-
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
ACTIVE NOT RECRUITING · Phase 2
-
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
RECRUITING · Phase 1
-
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
RECRUITING · Phase 1
-
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI